Artelo Biosciences To Present Data For Its ART27.13 To Treat Chemotherapy-Induced Neuropathic Pain At IASP 2026 World Congress On Pain
Benzinga Newsdesk 2 days ago
News
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with obesity, cancer, pain, dermatologic and neurological conditions, today announced that it will present data demonstrating the potential of ART27.13 to treat chemotherapy-induced neuropathic pain at the IASP 2026 World Congress on Pain, taking place October 26–30, 2026, in Bangkok, Thailand.